Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00254332 · ClinicalTrials.gov registry record
Effect of Denileukin Diftitox on Immune System in CTCL Patients
A clinical trial of Cutaneous T Cell Lymphoma and Mycosis Fungoides, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT00254332 is a study of Cutaneous T Cell Lymphoma and Mycosis Fungoides that has completed, run by University of Pittsburgh. The registered enrollment target is 10 participants, below the 67-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00254332, a study of Cutaneous T Cell Lymphoma and Mycosis Fungoides, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a blood and tissue study to determine the effect of the drug called denileukin diftitox on the immune system cells that may be involved in patient response to their cutaneous t-cell lymphoma. Patients who are undergoing standard of care therapy with denileukin diftitox will be invited to participate. Blood and tissue samples will be obtained at baseline, day 5 and day 19 in up to the first 4 cycles of denileukin diftitox.
Conditions Studied
Study Locations (1)
Pennsylvania
- University of Pittsubrgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00254332
The ClinicalTrials.gov registry entry for NCT00254332 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 67-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (85% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cutaneous T Cell Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT00254332 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00254332 about?
NCT00254332 is a clinical study titled "Effect of Denileukin Diftitox on Immune System in CTCL Patients". This is a blood and tissue study to determine the effect of the drug called denileukin diftitox on the immune system cells that may be involved in patient response to their cutaneous t-cell lymphoma. Patients who are undergoing standard of care therapy with denileukin diftitox will be invited to pa...
What is the current status of trial NCT00254332?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2005-11. Estimated completion is 2007-09.
What conditions does trial NCT00254332 study?
This clinical trial studies the following conditions: Cutaneous T Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome.
Who is sponsoring clinical trial NCT00254332?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00254332 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous T Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Photopheresis in Early-stage Mycosis Fungoides
RECRUITING · Phase 2
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Characterization of the Microbiome in Cutaneous T Cell Lymphoma
RECRUITING
-
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
RECRUITING · Phase 1
-
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
RECRUITING · Phase 1
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.